Richard has over a decade of experience working in biotech across investment banking, venture capital / public equity investing, and as a cofounder of venture backed biopharma companies.  He is currently the founder of Bay Bridge Bio, a research firm focused on biotech financial markets serving clients ranging from venture funds, growth-stage startups, university endowments and large corporations.  Bay Bridge Bio also creates free educational content and resources to help grad students, postdocs and early-mid career scientists learn about the biotech startup and investing world.

Josh has spent his career in the life science industry in senior leadership roles of operating companies as well as on the investment side in equity research and portfolio management. Prior to co-founding CUREX in 2019, Josh was a buy-side research analyst covering the biotech and medtech sectors for a firm with approximately $3 billion in assets during his tenure. Josh has previously led pre-clinical drug development for a NASDAQ-listed biopharmaceutical company and co-founded a clinical stage company developing companion diagnostics for cancer immunotherapy. Josh attained his bachelor's, master's, and doctorate degrees in biomedical engineering from Vanderbilt University and his MBA from Emory University. He is co-author on papers published in peer-reviewed biomedical journals and is a co-inventor on multiple patents. Josh also currently holds a part-time adjunct appointment as Assistant Professor in the Department of Biomedical Engineering at Vanderbilt University.